Board of Directors

MICHAEL MOORE DSc (Hons) PhD (Chairman)

Dr Moore has extensive experience in drug discovery and development and is currently a non-executive director of several private and public bioscience companies, including Mission Therapeutics, of which he was Founder Chairman, NASDAQ-listed Trillium Therapeutics Inc. and Mironid Limited.  He is currently Chairman of Chronos Therapeutics and was Founder Chairman of PsiOxus Therapeutics.  Dr Moore was previously CEO of Piramed, acquired by Roche in 2008, and Research Director and CSO of Xenova Group plc. Prior to joining the UK biotechnology sector, he had an extensive academic research career, principally at the Paterson Institute for Cancer Research and the University of Manchester Medical School, where he was Honorary Reader in immunology and oncology.  Dr Moore holds PhD and DSc degrees from the University of Nottingham, fellowship of the Royal College of Pathologists and is a past Chairman of Cancer Research UK’s drug discovery committee.

ANKER LUNDEMOSE (Independent Non-Executive Director)

Anker is currently Chief Executive Officer of Mission Therapeutics Ltd in Cambridge, UK. In a biopharma career spanning over twenty-five years, Anker has extensive experience from business and corporate development as well as R&D in several key therapeutic areas including oncology, diabetes and anti-infectives. He has a comprehensive international experience and network and has been responsible for successful mergers and acquisitions within biotech, venture investments and licensing. His background includes biotech start-ups, large biotech and big pharma, as well as an initial career in academia. Anker is a qualified medical doctor and has obtained his MD, PhD and DMSc degrees from the University of Aarhus, Denmark.

IAN MISCAMPBELL (Non-Executive Director)

Ian has served as Chief Finance Officer and as Chief Operating Officer in a number of publicly quoted and privately owned healthcare and drug development companies, including Reneuron, KS Biomedix, Microscience, Oxford Immunotec, William Ransom and York Pharma. He was responsible for numerous M&A and licensing transactions and has completed multiple financing and re-financing transactions, successfully raising in excess of £100m in equity, debt and grant finance.

Having worked as Finance Director in a healthcare fund management business, Ian left in 2010 to establish Sixth Element Capital, where he is Managing Partner. Ian was appointed a Fellow of the Institute of Chartered Accountants in England and Wales in 2011.

MARK KRUL (Non-Executive Director)

Mark has been involved in therapeutic drug development since 1993 and has a background in molecular biology and immunology. Before founding Aglaia BioMedical Ventures in 2003 he was Program Director of the NDDO Research Foundation. He held several positions at NDDO Oncology BV (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies (1997-2002). From 1993 till 1997 Mark has been Research Manager of the European Cancer Center and headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989 till 1993.

HAKAN GOKER (Non-Executive Director)

Hakan is a senior investment director at Merck Ventures, corporate venture arm of the Biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Hakan joined Merck Ventures in 2013 and previously was investing as a partner at Aescap Venture and prior to that at Atlas Venture. Since 2006, Hakan was instrumental in the creation, financing, and strategy of multiple biotechnology companies globally including Asceneuron (CH), Orphazyme (DK), Nimbus Discovery (US), F Star (NL), Bicycle Therapeutics (UK) and Nitec now Horizon Pharma (CH/US). Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is currently a board member of Asceneuron, Artios Pharma, Forendo, Raze Therapeutics, Tocopherx, Synaffix, and Storm Therapeutics.

SØREN BREGENHOLT PhD (Chief Executive Officer, Macrophage Pharma)

Dr Bregenholt is a seasoned life science executive with over 20 years of experience in operational and strategic leadership positions in biotech and global pharma including Symphogen, where he served as Chief Operating Officer and Head of Preclinical R&D and Novo Nordisk where he held a number of executive positions including Head of Global R&D Strategy & External Innovation organization.

Dr Bregenholt joined Macrophage pharma in July 2019, from a role as Chief Business Officer at IO Biotech. Dr Bregenholt has an MSc and PhD from the University of Copenhagen, and did his post-doctoral training at Institute Pasteur, Paris, and he is the author of more than 45 peer reviewed papers within the fields of immunology and immunopathology. He is currently Chairman of the Board at the Danish-Swedish life science organization Medicon Valley Alliance.